auto ‐ HCT (n = 6) or allogeneic ‐ HCT (n = 6) with or without radiotherapy (RT), and RT alone (n = 1); of pts with assessments 1 year after auto ‐ HCT and allo ‐ HCT, 5/6 and 5/5 had CR, respectively. Four pts remained progression ‐ free in FU for 137 + , 273 + , 372 + , and 606 + days after discontinuation of NIVO + BV (3 due to maximum clinical benefit and 1 due to study drug toxicity) without receiving subsequent therapy. The OS rate was 79% (95% CI, 59–90) at 12 months and 76% (95% CI, 55–88) at 24 months; median OS was not reached. Any ‐ grade treatment ‐ related adverse events (TRAEs) occurred in 83% of pts, most frequently neutropenia (30%; all grade 3–4) and peripheral neu-ropathy (27%; 10% grade 3–4). TRAEs led to discontinuation in 6 pts. No graft ‐ versus ‐ host disease was reported in the 6 pts receiving subsequent allo ‐ HCT. There were 8 deaths, 5 due to disease progression and none considered related to study drug toxicity. Conclusions: In this extended FU of CheckMate 436, NIVO + BV demonstrated durable responses and long ‐ term survival benefits; 4 pts remained progression ‐ free without consolidation after NIVO + BV. Safety was consistent with prior findings. These results further support NIVO + BV as a treatment option for pts with R/R PMBL.